MRI Interventions has signed a strategic agreement with Voyager Therapeutics to develop treatments for severe neurological diseases.
As part of the collaboration, MRI Interventions will contribute its ClearPoint neurological navigation system and SmartFlow neuroventricular cannula, an MRI-compatible injection and aspiration cannula for use in the brain. SmartFlow is compatible with ClearPoint.
The products will be used in Voyager Therapeutics' planned phase II/III program for its aromatic L-amino acid decarboxylase (AADC) gene therapy, known as VY-AADC, for Parkinson's disease.
In addition, the companies plan to jointly develop new minimally invasive neurosurgical devices using real-time MRI guidance, including new hardware, software, and cannulas for other Voyager Therapeutics gene therapies.
